OR WAIT null SECS
September 10, 2021
ILC Therapeutics, has successfully closed a £3.5 million (US$4.9 million) pre-initial public offering (IPO) funding round.
NICE has reconsidered its decision on Janssen's Erleada (apalutamide), issuing two positive final appraisal determinations (FADs) on the therapy.
NICE has recommended tofacitinib (Xeljanz, Pfizer)as an option for treating active polyarticular juvenile arthritis and juvenile psoriatic arthritis.
Sterling Pharma Solutions has invested in a center of excellence for research into commercial applications of continuous flow chemistry at its site in Dudley, UK.
Nanoform and Herantis Pharma's proof of concept project evaluating the application of the nanoforming process has been successful.
Avantor has acquired the Masterflex bioprocessing business and related assets of Antylia Scientific.
The White House announced a nearly $3 billion program to ramp up production of vaccines and their components.
September 09, 2021
Moderna announced a collaboration to develop a new mRNA therapeutic for Crigler-Najjar Syndrome Type 1 at no cost to patients.
Ardena acquires Idifarma, adding spray drying technology and high potency capabilities.
The orphan drug designation for TCR² Therapeutics’ Gavo-cel will facilitate research into a treatment for cholangiocarcinoma.